---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045598"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:53:46.761715+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TransCode receives Nasdaq delisting notice; plans to appeal bid-price deficiency

## Summary
- Company received Nasdaq notice on May 6, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive days (Mar 24–May 5).
- Due to multiple reverse stock splits over prior two years (cumulative ratio >=250:1), Company is ineligible for standard compliance period; must appeal by May 13, 2025.
- TransCode plans to timely request a hearing before a Nasdaq Hearings Panel; delisting stayed pending hearing outcome.
- No assurance the Company will ultimately regain compliance or remain listed on Nasdaq.

## SEC filing metadata
- accession: 0001104659-25-045598
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925045598/0001104659-25-045598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925045598/tm2514386d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045598
- JSON: https://secwatch.observer/filing/0001104659-25-045598.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.